Atypical femoral fracture following bisphosphonate treatment in a woman with osteogenesis imperfectaa case report

Acta Orthopaedica

Volumn 83, Issue 5, 2012, Pages 548-550

  Meier, Raphael P H ^a   Lorenzini, Kuntheavy Ing ^a   Uebelhart, Brigitte ^a   Stern, Richard ^a   Peter, Robin E ^a   Rizzoli, René ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; COLECALCIFEROL; COLLAGEN TYPE 1; ESTRADIOL;

AGED; ARTICLE; BONE DENSITOMETRY; BONE FRAGILITY; CASE REPORT; DRUG EFFICACY; DRUG WITHDRAWAL; ESTROGEN THERAPY; FEMALE; FEMUR FRACTURE; FOLLOW UP; FRACTURE HEALING; HUMAN; INTRAMEDULLARY NAIL; LEG PAIN; OSTEOGENESIS IMPERFECTA;

AGED; ALENDRONATE; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; FRACTURE FIXATION, INTRAMEDULLARY; HUMANS; OSTEOGENESIS IMPERFECTA;

EID: 84867857256     PISSN: 17453674     EISSN: 17453682     Source Type: Journal    
DOI: 10.3109/17453674.2012.729183     Document Type: Article

References (23)

1. Adami S, Gatti D, Colapietro F, et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 2003; 18 (1): 126-30.
2. Bornemann M, Saxon J R,Kidd G S, 2nd. Osteoporosis unmasked by hyperthyroidism in a young man with osteogenesis imperfecta. Arch Intern Med 1987; 147 (11): 1947-8.
3. DiMeglio L A,Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 2006; 21 (1): 132-40.
4. Durchschlag E, Paschalis E P, Zoehrer R, et al. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 2006; 21 (10): 1581-90.
5. Gatti D, Antoniazzi F, Prizzi R, et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. J Bone Miner Res 2005; 20 (5): 758-63.
6. Ing-Lorenzini K, Desmeules J, Plachta O, et al. Low-energy femoral fractures associated with the long-term use of bisphosphonates: A case series from a Swiss university hospital. Drug Saf 2009; 32 (9): 775-85.
7. Letocha A D, Cintas H L, Troendle J F, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 2005; 20 (6): 977-86.
8. Mashiba T, Turner C H, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28 (5): 524-31.
9. Mashiba T, Mori S, Burr D B, et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab (Suppl) 2005; 23 36-42.
10. Meier R P, Perneger T V, Stern R, et al. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 2012; 172 (12): 930-6.
11. Pauwels F. Die Bedeutung der Bauprinzipien des Stutz-und Bewegungsapparates fur die Beanspruchung der Röhrenknochen. Z Anat Entwicklungsgesch 1948; 114 (1-2): 129-66.
12. Phillipi C A, Remmington T, Steiner R D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 2008; (4): CD005088.
13. Rauch F, Glorieux F H. Osteogenesis imperfecta. Lancet 2004; 363 (9418): 1377-85.
14. Rizzoli R, Akesson K, Bouxsein M, et al. Subtrochanteric fractures after longterm treatment with bisphosphonates: A European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011; 22 (2): 373-90.
15. Sakkers R, Kok D, Engelbert R, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: A 2-year randomised placebo-controlled study. Lancet 2004; 363 (9419): 1427-31.
16. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364 (18): 1728-37.
17. Seikaly M G, Kopanati S, Salhab N, et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop 2005; 25 (6): 786-91.
18. Shabat S. Osteogenesis imperfecta-induced migratory stress fractures in a military recruit. Clin Exp Rheumatol 2000; 18 (5): 654.
19. Shane E, Burr D, Ebeling P R, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25 (11): 2267-94.
20. Spotila L D, Constantinou C D, Sereda L, et al. Mutation in a gene for type I procollagen (COL1A2) in a woman with postmenopausal osteoporosis: evidence for phenotypic and genotypic overlap with mild osteogenesis imperfecta. Proc Natl Acad Sci U S A 1991; 88 (12): 5423-7.
21. Tan S C, Koh S B, Goh S K, et al. Atypical femoral stress fractures in bisphosphonate-free patients. Osteoporos Int 2011; 22 (7): 2211-2.
22. Visekruna M, Wilson D,McKiernan F E. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metsb 2008; 93 (8): 2948-52.
23. Wekre L L, Froslie K F, Haugen L, et al. A population-based study of demographical variables and ability to perform activities of daily living in adults with osteogenesis imperfecta. Disabil Rehabil 2010; 32 (7): 579-87.